Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Fumihiro Tanaka



Author of

  • +

    P1.03 - Chemotherapy/Targeted Therapy (ID 689)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P1.03-027 - Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study) (ID 8490)

      09:30 - 16:00  |  Author(s): Fumihiro Tanaka

      • Abstract

      Background:
      The study objective was to compare efficacy and safety of CBDCA+PTX+BEV and CDDP+PEM+BEV in non-squamous (non-Sq) NSCLC patients.

      Method:
      Treatment-naïve patients aged 20-74 with advanced or recurrent EGFR/ALK-negative non-Sq NSCLC were randomly assigned at 1:2 ratio to either treatment A (4 cycles of CBDCA [AUC 6] + PTX [200mg/m[2]] + BEV [15mg/kg] q3wk, and maintenance therapy with BEV q3wk until progression) or treatment B (4 cycles of CDDP [75mg/m[2]] + PEM [500mg/m[2]] + BEV q3wk, and maintenance therapy with PEM + BEV until progression). The primary endpoint was PFS by central review. The secondary endpoints included OS and safety profile. Target enrollment number was 210.

      Result:
      A total of 55 sites across Japan enrolled 199 patients: 67/132 (A/B). The median age was 67/66 years, 70%/74% were male, 54%/52% were PS 0, 75%/73% were stage IV and 93%/98% had adenocarcinomas. As of April 14, 2017, patients had completed a median of 7/8 treatment cycles, while 94%/80% had discontinued treatment. The most common ≥G3 adverse events were neutropenia (75%/24%), and hyponatraemia (6%/10%). The most common BEV-related adverse events (≥G1) were hypertension (44%/58%), proteinuria (52%/43%) and epistaxis (26%/14%). Dose reduction was necessary due to an adverse event in 31%/22% patients. Treatment-related death (pulmonary infection) was reported in 1 patient receiving treatment B.

      Conclusion:
      CBDCA+PTX+BEV and CDDP+PEM+BEV had different safety profiles. Efficacy results including the primary endpoints will be presented in 2018.

  • +

    P1.07 - Immunology and Immunotherapy (ID 693)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Immunology and Immunotherapy
    • Presentations: 1
    • +

      P1.07-030 - Prognostic Impact of PD-L1 Expression in Correlation with HLA Class I Expression Status in Adenocarcinoma of the Lung (ID 9975)

      09:30 - 16:00  |  Author(s): Fumihiro Tanaka

      • Abstract

      Background:
      Programmed death-ligand 1 (PD-L1) and human leukocyte antigen (HLA) class I, expressed on tumor cells are important roles in cancer immunity. The current study was conducted to assess prognostic impact of PD-L1 status in correlation with HLA class I status in lung adenocarcinoma.

      Method:
      A total of 166 patients with completely resected lung adenocarcinoma were retrospectively reviewed. PD-L1 expression on tumor cells was evaluated with immunohistochemistry, in correlation with several clinicopathological and molecular features including HLA class I expression on tumor cells.

      Result:
      Twenty-one patients (12.7%) had tumor with positive PD-L1 expression (percentage of tumor cells expressing PD-L1, ≥ 5%), and the incidence was higher in smokers with higher smoking index and in poorly differentiated tumor. There was no significant correlation between HLA class I expression and PD-L1 expression. PD-L1 positivity provided no prognostic impact for all patients, but seemed to be correlated with a poor prognosis among patients with normal HLA class I expression (p=0.145). When only p-stage I patients were analyzed, PD-L1 positivity was a significant factor to predict a poor survival (5-year survival rate, 66.7% versus 85.9%; P=0.049), which was enhanced in tumor with normal HLA class-I expression (P=0.029) but was not evident in tumor with reduced HLA class I expression (P=0.552)

      Conclusion:
      The prognostic impact of PD-L1 expression on tumor cells in resectable lung adenocarcinoma was distinct according to HLA class I expression on tumor cells.

  • +

    SH 04 - WCLC 2017 Highlights of the Previous Day (ID 754)

    • Event: WCLC 2017
    • Type: Scientific Highlights
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      SH 04.02 - Locally Advanced NSCLC & Radiotherapy (ID 10933)

      07:00 - 08:00  |  Presenting Author(s): Fumihiro Tanaka

      • Abstract
      • Presentation
      • Slides

      Abstract not provided

      Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.